Table 1.
Improvements in OAB symptoms from Phase 1 and Phase 2 (paired t-test).
| Mean Pre-Treatment Symptom Severity (0–4) ± SD | Mean Post-Treatment Symptom Severity (0–4) ± SD | Improvement | p-Value | ||
|---|---|---|---|---|---|
| Urinary Frequency | |||||
| Phase 1 (n = 164) |
1.41 ± 1.2 * | 0.94 ± 1.1 * | 0.48 (33.8%) * | <0.05 | |
| Phase 2 (n = 64) |
1.31 ± 1.2 * | 0.57 ± 0.7 * | 0.74 (56.5%) * | <0.05 | |
| Urinary Urgency | |||||
| Phase 1 (n = 160) |
2.48 ± 1.0 * | 1.74 ± 1.0 * | 0.74 (29.8%) * | <0.05 | |
| Phase 2 (n = 47) |
1.83 ± 0.9 | 1.68 ± 1.1 | 0.15 (8.0%) | =0.40 | |
| Nocturia | |||||
| Phase 1 (n = 166) |
1.74 ± 1.1 * | 1.22 ± 1.0 * | 0.52 (29.8%) * | <0.05 | |
| Phase 2 (n = 51) |
1.31 ± 0.9 | 1.06 ± 1.0 | 0.25 (19.0%) | 0.05 | |
| Urinary Urge Incontinence | |||||
| Phase 1 (n = 160) |
2.06 ± 1.2 * | 1.42 ± 1.0 * | 0.64 (31.0%) * | <0.05 | |
| Phase 2 (n = 47) |
2.09 ± 1.1 | 1.38 ± 0.9 | 0.71 (34.0%) | =0.47 | |
* denotes statistically significant result.